Anterior vs CoverMyMeds (McKesson)
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Anterior | CoverMyMeds (McKesson) | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Payer enterprise deals only | Free to providers (funded by payers/pharma) · Payers, PBMs, pharma fund the network |
| Speed to go live | Embedded team, deep payer integration | Free self-serve portal; EHR-embedded options exist |
| Automation model | AI copilot · Clinician-in-loop utilization review | Data / network utility · medication ePA network and portal |
| Built for | Payers | Small practices, Mid-size groups, Enterprise systems, Payers |
| Security posture | HIPAA | No certifications published |
| Company maturity | 3 yrs (est. 2023) | 18 yrs (est. 2008) |
| Financial backing | $64M · Series B | Subsidiary of McKesson |
| Named customers | 1 named | None public |
| Published results | Specific numbers public | No public numbers |
| Documented integrations | 1 listed | 5 listed |
| Third-party validation | KLAS / analyst cited | None found |
Bottom line
- Pick Anterior if you are a health plan that wants clinician-supervised AI to cut prior auth review time while keeping final decisions with your own staff.
- Pick CoverMyMeds if you want free electronic prior auth for medications with the broadest payer and pharmacy network.
Anterior
Clinician-led AI for health plan clinical reviews
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series B
- Raised
- $64M
What it does
- AI clinical reasoning against payer medical policies
- Prior authorization review with nurse-in-the-loop workflow
- Auto-approval of clean requests, flagging of edge cases
- Embedded clinicians who tune accuracy in production
- Audit trails for every determination
- Five-day average deployment into plan workflows
Where it's strong
- Clinical accuracy of 99.24% in live production was independently validated by KLAS Research.
- Founded and staffed by clinicians, which helps with medical director buy-in inside plans.
- Deploys into existing UM workflows in days rather than the multi-month integrations typical of payer software.
What buyers should weigh
- Sells only to payers, so provider organizations looking for a submission-side tool are not the buyer.
- Young company with a small number of named reference customers, so diligence on scale is warranted.
- State laws increasingly require licensed clinicians to make denial decisions, so buyers must define where AI output stops and human judgment starts.
Named customers
Geisinger Health Plan
Integrations
CoverMyMeds (McKesson)
The largest electronic prior authorization network for medications
- Founded
- 2008
- HQ
- Columbus, OH
- Stage
- Subsidiary of McKesson
- Raised
- n/a
What it does
- Electronic prior authorization for retail and specialty drugs
- Specialty enrollment and hub services (RxLightning)
- Medical benefit PA for oncology and radiology (FastAuth)
- Benefit checks and prescription price transparency
- Patient affordability and copay program delivery
Where it's strong
- Network effects are real: it completed 43 million prior authorizations in the 2025 reverification season and most prescribers already have accounts.
- Free for providers and pharmacies, which makes adoption easy.
- McKesson ownership ties it into specialty distribution and pharma services that competitors cannot match.
What buyers should weigh
- Coverage is payer-dependent and shifting: Independence Blue Cross dropped CoverMyMeds for Surescripts ePA in August 2025, so verify your payer mix routes through it.
- It centers on medication PA; medical benefit and procedure prior auth needs mostly require other tools despite the FastAuth acquisition.
- Its revenue comes from pharma and payers, so provider-side feature priorities can lag.
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.